Research Platform
Beyond GB-101
Synaptiva would establish General Biotech's broader Neuromodulation Platform, supporting future compounds targeting receptors, enzymes, transporters and signaling pathways involved in neurological function.
Target Classes
Four classes the platform is built around
Receptors
Muscarinic, dopaminergic, serotonergic and adrenergic families modeled across conformational states, with orthosteric and allosteric sites treated as distinct design surfaces.
Enzymes
Turnover enzymes such as AChE, approached through controlled partial modulation rather than maximal inhibition.
Transporters
Reuptake machinery that governs how long a signal persists in the synaptic cleft and how quickly a system resets.
Signaling Pathways
Downstream intracellular cascades where multiple receptor inputs converge into a single functional outcome.
Workflow
A repeatable design loop
- 01Model
Structure-based receptor and enzyme models built for each target class, reused across every program.
- 02Predict
Docking and multi-target profiling to estimate an entire interaction fingerprint, not a single affinity value.
- 03Engineer
Iterative scaffold design that tunes the balance between intended activities and selectivity boundaries.
- 04Validate
Prioritized experimental testing to confirm, revise or discard each computationally predicted activity.